51432
当前位置: 首页   >  课题组新闻   >  Our project on O-GlcNAc modification (roles of protein O-GlcNAcylation in HBV infection and HCC)
Our project on O-GlcNAc modification (roles of protein O-GlcNAcylation in HBV infection and HCC)
发布时间:2024-02-24
  1. Zhou P, Chang WY, Gong DA, Xia J, Chen W, Huang LY, Liu R, Liu Y, Chen C, Wang K*, Tang N*, Huang AL*High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate. Cell Metab2023 Oct 4; doi: 10.1016/j.cmet.2023.09.009. PubMed PMID: 37797623.


  2. Feng Z, YinJ, Zhang Z, Chen Z, Huang L*, Tang N*, Wang K* O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation. Oncogene2024 Feb 23;doi: 10.1038/s41388-024-02977-7. PubMed PMID: 38396292.

  3. Yang Y#, Yan Y#, Yin J#, Tang N#Wang K#, Huang L, Hu J, Feng Z, Gao Q, Huang A*. O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal Transduct Target Ther. 2023 Feb 10;8(1):63doi: 10.1038/s41392-023-01316-8. PubMed PMID: 36765030; PubMed Central PMCID: PMC9918532.

  4. Hu J, Gao Q, Yang Y, Xia J, Zhang W, Chen Y, Zhou Z, Chang L, Hu Y, Zhou H, Liang L, Li X, Long Q, Wang K*, Huang A*, Tang N*Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation. Theranostics2021;11(2):805-823doi: 10.7150/thno.50230. eCollection 2021. PubMed PMID: 33391506; PubMed Central PMCID: PMC7738853.

  5. Xiang J, Chen C, Liu R, Gou DChang L, Deng H, Gao Q, Zhang W, Tuo L, Pan X, Liang L, Xia J, Huang L, Yao K, Wang B, Hu Z, Huang A*, Wang K*, Tang N*. Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. J Clin Invest. 2021 Apr 15;131(8)doi: 10.1172/JCI144703. PubMed PMID: 33690219; PubMed Central PMCID: PMC8262473.

  6. Zhou P, Chang WY, Gong DAHuang LY, Liu R, Liu Y, Xia J, Wang K*, Tang N*, Huang AL*. O-GlcNAcylation of SPOP promotes carcinogenesis in hepatocellular carcinoma. Oncogene2023 Jan 5;doi: 10.1038/s41388-022-02589-z. PubMed PMID: 36604567.

  7. Liu R, Gou D, Xiang J, Pan X, Gao Q, Zhou P, Liu Y, Hu J, Wang K*, Tang N*. O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis. Oncogene2021 Dec;40(50):6707-6719doi: 10.1038/s41388-021-02058-z. Epub 2021 Oct 14. PubMed PMID: 34650217; PubMed Central PMCID: PMC8677624.

  8. Shan X, Jiang R, Gou D, Xiang J, Zhou P, Xia J, Wang K, Huang A, Tang N*, Huang L*Identification of a diketopiperazine-based O-GlcNAc transferase inhibitor sensitizing hepatocellular carcinoma to CDK9 inhibition. FEBS J2023 May 29;doi: 10.1111/febs.16877. PubMed PMID: 37247228.